IntraCellular Therapies (ITCI)
(Real Time Quote from BATS)
$76.00 USD
+1.93 (2.61%)
Updated Jul 10, 2024 02:22 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ITCI 76.00 +1.93(2.61%)
Will ITCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITCI
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Other News for ITCI
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success
Intra-Cellular just downgraded at UBS, here's why
Intra-Cellular Therapies (ITCI) Receives a Buy from RBC Capital
Biotech Alert: Searches spiking for these stocks today
Intra-Cellular price target raised by $4 at Mizuho, here's why